SLC16A1 and cancer: An additional study in bladder cancer [27], and also studies in the GIST [51] and cancer of unknown primary origin [55] reported that OS [27,55] and disease-free survival (DFS) [27,51] were negatively affected when MCT1 and CD147 where co-expressed; this correlation was maintained for decreased OS when co-expression was observed in cisplatin-treated bladder cancer patients [27].